News | July 07, 2022
Lonza to build large-scale fill & finish facility in Switzerland
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Based on a post hoc analysis, fewer required respiratory interventions
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Subscribe To Our Newsletter & Stay Updated
